A phase I/IIa trial of VBI-1901 in patients with recurrent glioblastoma multiforme

Trial Profile

A phase I/IIa trial of VBI-1901 in patients with recurrent glioblastoma multiforme

Planning
Phase of Trial: Phase I/II

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs VBI 1901 (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; First in man
  • Sponsors VBI Vaccines
  • Most Recent Events

    • 28 Aug 2017 According to a VBI Vaccines media release, the company expects to initiate the enrollment in this study in the second half of 2017.
    • 15 Aug 2017 According to a VBI Vaccines media release, the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug Application (IND) for VBI-1901 and the comapny will initiate Phase I/2a study of VBI-1901 in patients with recurrent GBM in the second half of 2017.
    • 10 Nov 2016 According to a VBI Vaccines Inc. media release, company anticipates filing an Investigational New Drug ("IND") application with the U.S. FDA in the first half of 2017 to initiate this study and also Fast Track designation will be considered during IND submission.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top